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Abstract
The low frequency of p53 alterations e.g., mutations/deletions (,10%) in multiple myeloma (MM) makes this tumor type an
ideal candidate for p53-targeted therapies. RITA is a small molecule which can induce apoptosis in tumor cells by activating
the p53 pathway. We previously showed that RITA strongly activates p53 while selectively inhibiting growth of MM cells
without inducing genotoxicity, indicating its potential as a drug lead for p53-targeted therapy in MM. However, the
molecular mechanisms underlying the pro-apoptotic effect of RITA are largely undefined. Gene expression analysis by
microarray identified a significant number of differentially expressed genes associated with stress response including c-Jun
N-terminal kinase (JNK) signaling pathway. By Western blot analysis we further confirmed that RITA induced activation of
p53 in conjunction with up-regulation of phosphorylated ASK-1, MKK-4 and c-Jun. These results suggest that RITA induced
the activation of JNK signaling. Chromatin immunoprecipitation (ChIP) analysis showed that activated c-Jun binds to the
activator protein-1 (AP-1) binding site of the p53 promoter region. Disruption of the JNK signal pathway by small interfering
RNA (siRNA) against JNK or JNK specific inhibitor, SP-600125 inhibited the activation of p53 and attenuated apoptosis
induced by RITA in myeloma cells carrying wild type p53. On the other hand, p53 transcriptional inhibitor, PFT-a or p53
siRNA not only inhibited the activation of p53 transcriptional targets but also blocked the activation of c-Jun suggesting the
presence of a positive feedback loop between p53 and JNK. In addition, RITA in combination with dexamethasone, known
as a JNK activator, displays synergistic cytotoxic responses in MM cell lines and patient samples. Our study unveils a
previously undescribed mechanism of RITA-induced p53-mediated apoptosis through JNK signaling pathway and provides
the rationale for combination of p53 activating drugs with JNK activators in the treatment of MM.
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Introduction
Although mutations in the p53 gene occur in half of all cancers,
approximately 90% of multiple myeloma (MM) cells retain a
functional wild type p53 [1–3]. The low frequency of p53
alterations (mutations/deletions) in MM makes this tumor type an
ideal candidate for p53-targeted therapies. Even in cancers
retaining wild-type p53, p53 function is effectively inhibited which
is primarily performed by the MDM2. Studies using small
molecule inhibitors of the p53-MDM2 interaction such as nutlin
and RITA (Reactivation of p53 and induction of tumor cell
apoptosis) have shown the potential for pharmacological activation
of p53 by disrupting the p53-MDM2 interaction as a new and
promising anticancer strategy [4–8].
We have previously demonstrated an anti-myeloma activity of
RITA mediated by activation of the p53 pathway [9]. RITA-
induced apoptosis was shown to be associated with up-regulation
of p53 and a pro-apoptotic target Noxa and down-regulation of
p21 and MDM2 and an anti-apoptotic target Mcl-1. In addition,
apoptosis was predominantly followed by extrinsic pathways [9].
Based on the previous reports on the apoptotic effect of RITA on
different types of solid tumors, RITA-induced apoptosis is thought
to be mediated by inhibition of the p53-MDM2 interaction by
binding of RITA with p53 [8,10–12]. However, a recent study by
Nuclear Magnetic Resonance (NMR) indicated that RITA does
not block the p53-MDM2 interaction in vitro [13]. Thus, whether
binding to p53 is the only mechanism by which RITA increases
p53 activity in cells is a matter of debate. It is highly possible that
that RITA-induced activation of the p53 pathway can also occur
in the mechanisms independent of inhibition of the interaction
between p53 and MDM2.
In non-stressed normally growing cells, p53 degradation is not
only mediated by its negative regulator MDM2, but also through
binding with inactive form of c-Jun NH2-terminal kinase (JNK),
which is one of the mitogen activated protein kinases (MAPKs),
also known as stress-activated protein kinase (SAPK) [14]. In
response to stress, JNK is activated through induction of cascades
of two major MAPK families: MAP3K including ASK1 and
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activation of MAP3K, MAP2K, and JNK, which eventually leads
to phosphorylation of c-Jun [16]. c-Jun is the founding member of
the activator protein-1 (AP-1) family of transcription factors which
bind to AP-1 elements in their target genes [17]. Recent studies
have shown that JNK can directly or indirectly modulate
expression of p53 and its targets and can positively influence
apoptotic cell death [14,18,19]. Since JNK in association with p53
plays an important role in p53 stability, activation of p53 by stress
and damage stimuli often correlates with induction of JNK [20].
Reportedly, JNK activation is one of the crucial pathways for
apoptosis induction by the leading anti-MM agents such as
proteasome inhibitors or immunomodulatory drugs (IMiDs), or
various new candidate agents for MM [21–24].
Although a variety of mechanisms has been proposed to explain
the activation of the p53 pathway in tumor cells there is still lack of
evidence for functional linkage between JNK signaling and p53.
The activation of the p53 pathway by RITA and the association of
JNK and p53 by other anti-MM agents led us suggest that
activation of the p53 by RITA may be mediated by JNK signaling
pathway. Here we provide the evidence that RITA-induced
activation of p53 in MM cells is dependent on JNK signaling.
Detailed insights into molecular signaling pathways involved in
RITA-induced apoptotic cell death may prove useful in the
development of p53 based therapeutic approaches and strategies
for JNK-mediated tumor targeting.
Materials and Methods
Patient samples and cell lines
Myeloma samples were collected from newly diagnosed
patients. This study received written approval from the University
Health Network Research Ethics Board in accordance with the
Declaration of Helsinki. Cultured MM cell lines (MM.1S, 8226
and 8226R5) were collected from different sources and maintained
as previously described [9]. NCI-H929, HeLa, MCF-7, and OCI-
AML-3 cell lines were obtained from American Type Culture
Collection (ATCC).
Drug treatment
RITA and nutlin were purchased from Cayman Chemical and
dissolved in dimethyl sulfoxide (DMSO) to create a 50 mM stock
solution and stored at -20uC. Etoposide was purchased from Enzo
Life Sciences (Farmingdale, NY). In each experiment, the final
DMSO concentration was kept constant and did not exceed
0.05% (vol/vol). In some experiments, cells were simultaneously
exposed to RITA and dexamethasone (DXM) (Cayman Chemical)
(or 2-Cyano-3,12-dioxooleana-1,9-dien-28 oic Acid (CDDO)
(REATA pharmaceuticals, TX). CDDO was prepared at
20 mM stock solutions in DMSO and was stored at -20uC.
JNK-specific inhibitor, SP600125 and p53-transcriptional inhib-
itor, PFT-a were purchased from InvivoGen (San Diego, CA) and
Enzo Life Sciences, respectively. After drug treatment, cells were
harvested and subjected to further analysis as described below.
Cell viability and apoptosis assays
Cell viability was assayed by MTT assay performed in triplicate
at least twice as previously described [9]. To examine apoptotic
cell death, MM cells were treated with various concentrations of
RITA in the absence or presence of a SP600125 or PFT-a and
stained for analysis by Flow cytometry with Annexin V-FITC
(Abcam, MA) and propidium iodide (Sigma-Aldrich, St. Louis,
MO). Data were analyzed using FlowJo software as described
previously [9].
Gene expression analysis and Quantitative Real Time PCR
(qRT-PCR)
Total RNA was isolated using TRIzol reagent (Invitrogen,
Carlsbad, CA) and the gene expression profile was evaluated using
Illumina RNA analysis Beadchips (Illumina Inc. San Diego, CA)
representing ,48,000 human genes (Human HT12) as described
earlier [9]. Expression of key genes in RITA-induced MM.1S cells
involved in cell proliferation, cell-cycle arrest or apoptosis was
analysed. To quantify and validate the expression of p53 target
genes of interest at their mRNA level, qRT-PCR assays using
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a refer-
ence gene were performed as described previously [9].
Immunoblotting
Western blot analysis of the whole cell lysates obtained from the
cells treated with RITA in the absence or presence of the inhibitors
or siRNAs were performed as described previously [9]. Primary
antibodies were from the following manufacturers: Santa Cruz
Biotechnology (Santa Cruz, CA): p53 (DO-7) and b-actin; Abcam:
NOXA; Cell Signaling Technology (Danvers, MA): Mcl-1, JNK1/
2, caspase-3 and PARP; Signalway Antibody (Pearland, TX): ASK-
1-p, MKK4-p, c-Jun, c-Jun-p and 4E-BP1; Biolegend (San Diego,
CA): a tubutlin. Goat anti-mouse and anti-rabbit secondary
antibodies conjugated to horseradish peroxidase were purchased
from Cell Signaling and Santa Cruz Biotechnology, respectively.
Genetic Knockdown of selective target genes
H929 or MM.1S cells were transfected with target specific
siRNAs for JNK (Sigma) or p53 (Invitrogen) or control scrambled
siRNA (Invitrogen) using the Cell Line Solution Kit V (Amaxa,
GmbH, Cologne, Germany) according to the manufacturer’s
instruction with the Amaxa Nucleofector II device (Amaxa).
Custom siRNA sequence for JNK simultaneously targets JNK1
and JNK2 [25]. Following transfection, cells were treated with
RITA and analysed for inhibition of activation of the p53 and
apoptotic targets including caspase-3 and PARP. The effect of cell
viability and apoptosis induction by RITA following the
knockdown of JNK or p53 was analysed by MTT assay and
FCM, respectively.
Chromatin immunoprecipitation (ChIP) assays
ChIP assays were performed in MM.1S and H929 cells treated
with RITA or DMSO control as described by Chen et al [26]. In
brief, formaldehyde cross-linked chromatin was isolated from
5610
7 cells followed by IP with phosphorylated c-Jun antibody or
normal rabbit immunoglobulin (IgG) bound to ChIP grade
sephadex A Bead (Cell Signaling) according to the manufacturer’s
instruction. DNA was eluted from the beads and reverse cross-
linked according to the protocol. Polymerase chain reaction was
used to analyze the immunoprecipitated DNA with the use of
primers against AP-1 binding site of p53 promoter region (fwd-
AGGAGCCTCGCAGGGGTTGAT, rev-CCAATCCAGGGA-
GTGTCACCG) or GAPDH (fwd-ACATCGCTCAGACAC-
CATG, rev-TGTAGTTGAGGTCAATGAAGGG).
Statistical analysis
The synergistic effect [combination index (CI) ,1.0] of the
combination of RITA and DXM or CDDO was analyzed using
CalcuSyn (Biosoft, Cambridge, UK), a software program based on
the Chou-Talalay method, as described previously [7,9]. An
isobologram is a graph that indicates affected fraction and CI.
Statistical significance levels were determined by two-tailed t test
analysis. p values of ,0.05 were considered significant.
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Gene expression profiling (GEP) by microarray identified
differentially expressed genes in JNK signaling pathway
Our GEP by microarray data of MM.1S cells treated with
RITA demonstrates transcriptional triggering of apoptotic cas-
cades, down-regulation of growth/survival kinases, up-regulation
of unfolded protein responses (UPR), and induction of stress
kinases. A total of 51 selected genes differentially expressed
between RITA-treated and DMSO control treated MM.1S cells
are represented in the heat map (Figure 1A).
To confirm the results of the gene expression by microarray,
qRT-PCR validation was performed on the RNA samples used for
the initial array. A full list of the validated primers can be found in
the Table S1. The expressions of the genes in RITA-induced
MM.1S cells by qRT-PCR (Figure 1B), were observed to have
consistent dysregulation between RITA-treated and control
DMSO-treated cells and were similar to those changes seen by
microarray analysis. Of note, ,2–4 fold increase in the stress
responsive genes, ATF3, ATF4, DDIT3, DDIT4, c-Jun and FOS,
was observed upon RITA-stimulation (Figure 1A, B). Consistent
with the p53 cellular functions, we found that 62 of the 229 genes
in RITA-induced MM.1S cells were involved in apoptosis, cell
cycle regulation, cell growth and differentiation, DNA repair and
chromatin modification, or transcription regulation. Importantly,
a significant number of genes (,46) were associated with different
types of stress signaling including p53 and JNK signaling
(Figure 1C, Table S2). Of greatest interest from the microarray
analyses was the ,3-fold up-regulation of c-Jun, one of the
substrates of JNK. These results indicated that JNK-mediated
signaling is involved in RITA-induced cell death in MM cells. We
subsequently focused our analysis on the activation of c-Jun/JNK
signaling.
To identify the most relevant biologic mechanisms, pathways,
and functional categories of the (229) genes affected by induction
of c-Jun, we used Ingenuity Pathways Analysis (IPA) software
(Ingenuity Systems, Redwood City, CA). Using IPA with false
discovery rate (FDR) of 10% and fold change cut-off of 62, we
Figure 1. RITA induces transcriptional regulation of a set of p53 target genes. Gene expression analysis by microarray in MM.1S cells after
6 hrs treatment with 1 mM RITA. (A) Shown is the heat map of genes differentially expressed in MM.1S cells. Vertical rows indicate separate arrays, and
horizontal rows indicate genes. A number of differentially expressed genes associated with stress responses are labeled with green and red lines.
Green indicates low expression; red indicates high expression. (B) mRNA levels of the genes were detected by qRT-PCR in MM.1S cells 6 hrs after
treatment with 1 mM RITA. Values were normalized to those obtained for GAPDH and expressed as log2 fold induction over DMSO treated cells (mean
6 SD). (C) Genes are categorized according to their functions and represented in the figure.
doi:10.1371/journal.pone.0030215.g001
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signaling pathways involving genes significantly dysregulated in
MM.1S cells treated with RITA or DMSO control. IPA analysis of
the 120 genes differentially expressed between RITA treated and
non-treated MM.1S cells revealed two significant networks which
target the JNK pathway (Figure S1). The two networks represent
the proteins associated with cell signaling, cellular growth and
proliferation, cell cycle, cellular development and JNK signaling
pathways. Molecules associated within these pathways are listed in
Table S2.
RITA induces activation of JNK in MM cells
JNK is responsible for the phosphorylation of a variety of
proteins including downstream kinases and transcription factors
such as c-Jun with subsequent transcriptional AP-1 activation [27].
Indeed, c-Jun phosphorylation is widely regarded as an inevitable
consequence of JNK activation. MM cell lines of different p53
status were treated with RITA and c-Jun amino terminal
phosphorylation was examined by immunoblotting using a
phospho-specific (Ser73) c-Jun antibody (Figure 2). We found that
treatment of myeloma cells (H929 and MM.1S) with RITA
resulted in a dose-dependent increase in the phosphorylation of c-
Jun. However, the protein level of total c-Jun remained relatively
constant during the course of treatment (Figure 2A). Based on this
data, we then attempted to identify the upstream signaling
molecules involved in the activation of JNK in cells treated with
RITA. Western blot analysis revealed that H929 or MM.1S cells
treated with RITA for 8 hrs induced phosphorylation of ASK-1
(Ser966) and MKK-4 (Ser80), representative members of MAP3K
and MAP2K family, respectively. These events were followed by
up-regulation of p53, and a pro-apoptotic protein, Noxa; down-
regulation of Mcl-1, an anti-apoptotic protein, and 4E-BP1, a
survival factor in JNK pathways (Figure 2A). We compared the
effect of RITA on c-Jun activation in the wild type p53 expressing
H929 and MM.1S cells with that in the 8226R5 p53 null and
mutant p53 expressing U266 cells. Interestingly, the activation of
c-Jun induced by RITA was found to be p53-independent, i.e., up-
regulation of phosphorylated c-Jun was not only observed in MM
cells harboring wild type p53 but also in cells harboring null or
mutant p53 (Figure 2B). However, as described in our previous
report, RITA induced apoptosis only in cells harboring wild type
p53 [9]. Kinetic analysis showed that RITA treatment induced
phosphorylated c-Jun level in H929 and MM.1S cells in a time-
dependent manner. Phosphorylation of ASK-1 and MKK4 was
also observed at the similar fashion (Figure 2C). These results are
in line with our previous study in which time-dependent activation
of p53 was observed in these two cells lines [9]. Taken together
these results demonstrate that RITA-induced apoptosis in MM
cells is mediated by activation of JNK signaling cascade.
Effect of other nongenotoxic or genotoxic drugs on JNK
activation in MM
Having shown that small molecule RITA induced activation of
JNK in MM cells, we examined whether the activation of JNK is
specific to RITA. MM.1S or H929 cells were treated with the
nongenotoxic small molecules nutlin or RITA and a genotoxic
agent etoposide and examined for activation of JNK. Western blot
analysis of the samples harvested from MM cells treated with these
agents revealed the phoshphorylation of c-Jun in cells treated with
RITA. However, phosphorylation of c-Jun was not significantly
modulated when the cells were treated with nutlin or etoposide.
These results suggest that activation of JNK in MM cells is RITA
specific (Figure 3A).
Effect of JNK activation induced by RITA in other cancer
cell types
Since RITA induced JNK activation in MM cells, we next
attempted to see whether RITA-induced activation of JNK can be
observed in other types of cancer cells. We evaluated the effect of
RITA on JNK activation in additional 3 different types of cell lines
harboring wild type p53, e.g., AML-3 (myeloid leukemia); HeLa
(cervical cancer); and MCF-7 (breast cancer). The activation of
p53 induced by RITA has been reported in HeLa [28] and MCF-
7 cell lines [12]. MM.1S cell line was used as a control for RITA
treatment. All cells were treated with 1 mM RITA for 8 hrs.
Although activation of p53 was found in all of the cell lines upon
RITA treatment, RITA-induced phosphorylation of c-Jun was
observed in MM.1S cells but phosphorylation level of c-Jun was
not significantly changed in other type of cells. These results
suggest that RITA-induced activation of JNK is likely specific to
myeloma cells (Figure 3B).
JNK specific inhibitor or JNK siRNA inhibited the
activation of p53 and p53-mediated apoptosis
In order to clarify the involvement of JNK, we first investigated
the role of JNK in the regulation of p53-mediated apoptosis
induced by RITA in MM cells by using a JNK specific inhibitor,
SP-600125 which exhibits significant selectivity for JNKs leading
to inhibition of both phosphorylation of c-Jun and JNKs [29]. To
this end, we treated H929 cells with RITA in the absence or
presence of SP-600125 and analyzed the expression of the proteins
associated with p53-mediated apoptosis (Figure 4). We found that,
presence of SP600125 abrogated the ability of RITA to up-
regulate phosphorylated c-Jun level. Concurrently, RITA-induced
p53 activation was also inhibited by SP-600125. In addition, the
up-regulation of Noxa, and down-regulation of 4E-BP1 and Mcl-1
induced by RITA also inhibited (Figure 4A). To further
understand specific inhibition of JNK activation, JNK was
selectively knocked down by siRNA approach. Similar to the
results obtained by pharmacological inhibitor of JNK, activation of
the phosphorylation of c-Jun as well as p53 was inhibited in JNK
knocked down H929 cells treated with RITA (Figure 4B).
Functionally, p53-dependent apoptosis of H929 cells was inhibited
by both SP-600125 and JNK siRNA as evidenced by reduction of
cleavage of caspase-3 and PARP by Western blot analysis
(Figure 4A,B) and inhibition in Annexin V binding by FCM
(Figure 4C). In addition, knocking down of JNK suppressed the
growth inhibitory effect of RITA in H929 cells (Figure 4D). These
results collectively indicate that activation of p53 induced by RITA
is mediated by the activation of JNK and strongly suggest that
JNK plays a critical role in mediating RITA-induced apoptosis.
Chromatin immunoprecipitation assay (ChIP) revealed
the binding of activated c-Jun to the p53 promoter
region
Having shown an important role of JNK signaling in p53
induction, we investigated whether RITA-induced activation of
p53 is mediated by direct binding of c-Jun in the AP-1 binding site
of the p53 promoter region. The p53 promoter contains a
conserved AP-1-like element that differs from a consensus AP-1
site by a single base-pair exchange (termed PF-1 site) [30]. The
binding of c-Jun to p53 promoter was studied by PCR using
primers that flank AP1 site which amplify a 350 bp region.
Phosphorylated c-Jun antibody immunoprecipitated an increased
proportion of the region of the p53 promoter containing AP-1 site
in both MM.1S and H929 cells treated with RITA, whereas the
control antibody (IgG) failed to precipitate it (Figure 5A).
Role of JNK Signaling in RITA Induced Apoptosis
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binding to the p53 promoter in RITA-treated MM.1S and H929
cells, respectively, in comparison to DMSO control treated cells
(Figure 5B). Our results clearly demonstrate that upon RITA
stimulation phosphorylated c-Jun binds to p53 promoter for the
induction of p53 transcriptional activity.
Inhibition of p53 transactivation by p53 transcriptional
inhibitor or p53 siRNA prevents activation of c-Jun
Given the roles of JNK associated with induction of p53-
mediated apoptosis in response to RITA, we next examined the
role of p53 transcription by using a p53 transcriptional inhibitor,
PFT-a, a specific inhibitor of p53 transcriptional targets. As shown
in Figure 5A, PFT-a inhibited the up-regulation of p53 and Noxa
as well as phosphorylation of c-Jun induced by RITA in H929
cells. Moreover, the apoptosis induction by RITA was also
inhibited by PFT-a as evidenced by inhibition of cleavage of
caspase-3 and PARP (Figure 6A) and inhibition of Annexin V
binding in both MM.1S and H929 cells with wild-type p53 but not
in U266 cells with mutant p53 (Figure 6B). These results suggest
that p53 is involved in RITA-induced apoptosis of MM cells and
confirm the linkage between p53 and JNK activation. To confirm
the p53-dependent induction of apoptosis by RITA, using siRNA
approach, we specifically knocked down p53 in MM.1S cells
which was followed by assessment of p53 targets and its apoptotic
effect. Silencing of p53 was associated with significant inhibition of
RITA-induced activation of Noxa and cleavage of caspase-3 and
PARP (Figure 6C). Importantly, similar to the results obtained
from the inhibition of p53 transcription by PFT-a, RITA-induced
phosphorylation of c-Jun was inhibited when p53 expression was
silenced by siRNA. These results suggest the establishment of a
positive feedback loop between p53 and JNK. In addition,
knockdown p53 expression attenuated the RITA-induced increase
of Annexin V-positive cells and inhibition of cell survival. For
example, apoptosis induction by RITA in MM.1S cells was
reduced from 52% to 15% in RITA-induced H929 cells
transfected with p53 siRNA. Similarly, silencing p53 in MM.1S
cells prevented the killing of cells mediated by RITA (Figure 6D).
These results further confirm that RITA-induced apoptosis in MM
cells is p53-dependent.
RITA in combination with other JNK activating drugs
displays synergistic cytotoxic responses
Having shown that RITA induces apoptosis via activation of the
JNK signaling pathway, we further examined the combined
cytotoxic effect of RITA and DXM, a conventional chemother-
apeutic as well as an activator of JNK [31]. The effects of
combination of RITA and DXM were assessed on the viability of
MM cell lines and primary MM samples. We examined possible
additive or synergistic anti-proliferative effects of RITA and DXM
following 48 hours of treatment of H929 cells with lower doses (1
and 2 mM) of RITA combined with 0.5 mM DXM. Treatment of
H929 cells with RITA or DXM alone induced only 10 to 40% cell
killing which was synergistically enhanced to 65% (CI, 0.88) and
Figure 2. RITA induces activation of JNK signaling in MM cells. (A) H929 and MM.1S cells (harboring wild type p53), and (B) 8226R5 (p53 null)
and U266 (p53 mutant) cell lines were treated with different concentrations of RITA for 8 hrs. (C) H929 or MM.1S cells were treated with 2.5 mMo r
1 mM RITA, respectively for different time periods (4–12 hrs). The cells were then harvested and subjected to preparation of whole-cell protein lysates
for detection of the indicated proteins by Western blot analysis.
doi:10.1371/journal.pone.0030215.g002
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combination (Table 1, Figure S2A). We next confirmed the
cytotoxic response of RITA in combination with DXM in MM
patient samples. The combination of 5 mM RITA and 1 mM
DXM induced a synergistic cytotoxicity (CI=0.5420.72) in 3
primary MM samples (Table 2, Figure S2B). The synergistic anti-
myeloma activity of the two agents was clearly demonstrated by a
leftward shift of the dose response curve as well as isobologram and
CI analyses in both H929 cell lines and primary MM samples
(Figure S2A,B). To further understand the clinical significance of
JNK activation in RITA-induced apoptosis we investigated the
cytotoxic effect of RITA by combining it with CDDO, a known
JNK activator [32]. First, dose responses of CDDO were
examined in MM.1S and H929 cells after treating the cells with
different concentrations of CDDO for 48 hrs. Results showed a
dose-dependent killing of MM cells by CDDO (Figure S3A). Next,
MM.1S or H929 cells were treated with low doses of RITA (0.25–
1.0 mM) with a fixed dose of CDDO (0.5 mM) for 48 hrs and
viability was measured. As shown in Figure S3B, in MM.1S cells
the combination of 0.5 mM CDDO with either 0.25 or 0.5 mM
RITA displayed a synergistic cytotoxic response with a CI value of
0.83 and 0.62, respectively. Similarly, combination of 0.5 mM
CDDO with 0.5 or 1.0 mM RITA showed a synergistic cytotoxic
response in H929 cells in which CI value was 0.92 and 0.87,
respectively.
Discussion
In this study, we demonstrated that RITA induces a potent
activation of JNK signaling in MM cells. GEP by microarray
identified a significant number of genes associated with stress
responses leading to apoptosis. Consistent with the up-regulation
of c-Jun as observed by microarray studies, we found that RITA-
induces phosphorylation of c-Jun in MM cells in a time and dose-
dependent manner which causes activation of p53 and cell death.
These results suggest the activation of JNK signaling in MM cells
upon stimulation by RITA. Activation of JNK by hgal9 (a
recombinant protease resistant galectin-9), or plinabulin (a novel
vascular disrupting agent), or perifosine (an Akt inhibitor) has
previously been reported in MM cells [23,24,33]. Accumulating
evidence has demonstrated that during apoptotic signaling, activity
of both of p53 and c-Jun, can be modulated through posttrans-
lational modifications by JNK cascade [14,15,34]. Stabilization
and activation of the p53 by JNK signaling has been described in
p53 null mouse fibroblast [14,15]. However, the functional linkage
between activation of p53 and JNK signaling has not been
elucidated in MM cells induced by p53 reactivating agents such as
RITA.
Here we provide the first line of evidence that the activation of
JNK has a crucial role for efficient induction of apoptosis by
pharmacologically activated p53. Off note, the activation of JNK
Figure 3. RITA-specific activation of JNK is selective to MM cells. (A) MM.1S or H929 cells were treated with RITA (1 mM for MM.1S or 2.5 mM
for H929), nutlin (5 mM), or etoposide (5 mM) along with DMSO control. 8 hrs after treatment, cells were harvested for Western blot analysis and
detected for the up-regulation of c-Jun-p and p53. C, N, R, and E indicate cells treated with DMSO control, nutlin, RITA and etoposide, respectively. (B)
Three different types of cells: AML-3 (myeloid leukemia), HeLa (cervical cancer), and MCF-7 (breast cancer) were treated with 1 mM RITA or DMSO for
8 hrs. MM.1S cells were treated in a similar manner as controls. The cells were harvested for analysis by Western blot which were probed with the
indicated antibodies.
doi:10.1371/journal.pone.0030215.g003
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compared to other nongenotoxic (nutlin) or genotoxic drugs
(etoposide). In addition, the JNK activation by RITA appears to
be more effective in MM cells in comparison to other tumor cell
types. Moreover, we found that induction of p53 is independent of
activation of JNK signaling, since RITA induces phosphorylation
of c-Jun in cells where p53 was mutated or null. The inhibition of
p53 activation upon silencing of JNK suggests that induction of
p53 signaling occurs downstream of JNK which is in contrast to
the previous studies where JNK activation was described as a
downstream event of p53 activation associated with activation of
EGR1 [26] and p73 [35]. Another important aspect of our study is
that inhibition of activation of p53 transcriptional targets by PFT-
a or p53 siRNA resulted in inhibition of phosphorylation of c-Jun.
These results indicate the establishment of a positive feedback loop
between p53 and JNK (Figure 8) potentiating the apoptosis
induction by RITA.
We have demonstrated that activation of JNK is playing an
apoptotic role in MM cells induced by RITA, which is consistent
with a previous observation showing the requirement of JNK
activation JNK for the stabilization of p53 and enhancement of
p53 trans-activation by abrogating MDM2 association in p53 null
fibroblast [15]. However, depending on the cellular context, c-Jun
may play a survival role. These opposing effects have previously
been reported for c-Jun and b-catenin, a key component of the
Wnt signaling pathway [35] as well as for p53 mediated JNK
activation [36]. Activation of JNK in these studies was described as
only a downstream event of p53 and inhibition of endogenous
JNK activity resulted in an increase of apoptosis in response to
nocodazole treatment of human colon carcinoma cells harboring
wild type p53 in the latter studies [36].
Based on our results we suggest a schematic model illustrating a
novel mechanism of p53-dependent JNK mediated induction of
apoptosis by RITA (Figure 8). Stimulation of MM cells by RITA
results in activation of JNK through JNK cascade and phosphor-
ylation of c-Jun, which induces p53 accumulation. Activated p53
in turn may enhance JNK signaling through a positive feedback
loop between p53 and JNK. JNK activation has previously been
shown to phosphorylate p53 (Ser 15) at its N-terminal activation
loop [37,38]. We observed activation of JNK in the absence of
Figure 4. JNK activation is required for RITA-induced apoptosis. H929 cells were pretreated with SP600125 for 30 min (A) or transfected with
scrambled or JNK siRNA for 24 hrs (B) and then treated with RITA for additional 8 hrs. The cells were then harvested and subjected to preparation of
whole-cell protein lysates for detection of the indicated proteins by Western blot analysis. Cleaved caspase-3 is indicated as cl. caspase-3. (C) H929
cells pre-treated with SP600125 or transfected with JNK siRNA were further treated with 2.5 mM RITA for 48 hrs. RITA treated H929 cells were analysed
by FCM for Annexin-V binding to measure the apoptosis. (D) Silencing of JNK suppresses RITA-induced cytotoxicity in MM cells. H929 cells transfected
with either JNK siRNA or negative-scrambled siRNA and 48 hours later cells were treated with RITA (2.5 mM) or DMSO. 48 hrs treatments, cell viability
were measured by MTT assay. *p ,0.05 versus the corresponding cells treated with RITA in the absence of SP600125 or transfected with scrambled
siRNA (Student’s t test).
doi:10.1371/journal.pone.0030215.g004
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PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e30215Figure 5. Activated c-Jun binds to AP-1 binding site of p53 promoter region. 8 hrs after exposure of MM.1S and H929 cells to 1 and 2.5 mM
RITA, respectively, cells were prepared for ChIP with phosphorylated c-Jun, or control IgG antibodies. Cells treated with DMSO were used as controls.
This was followed by PCR amplification of the target promoter sequence. (A) The normalized controls were performed by GAPDH for input DNA of
MM.1S and H929 cell lines. (B) Experiments were repeated twice, and the average fold differences in relative enrichment (ChIP/IgG) over the GAPDH
control is represented.
doi:10.1371/journal.pone.0030215.g005
Figure 6. Blocking of p53 transactivation inhibits RITA–induced apoptosis. (A) Inhibition of p53 transcription inhibits activation of c-Jun in
MM cells. H929 cells were pretreated with 15 mM PFT-a for 1 hr and then treated with 2.5 mM RITA for additional 8 hrs. The cells were then harvested
and subjected to preparation of whole-cell lysates for detection of the indicated proteins by Western blot analysis. (B) p53 transcriptional inhibitor
inhibits induction of apoptosis in MM cells harboring wild type p53. MM.1S, H929, and U266 cells were pretreated with PFT-a for 1 hr and then
treated with RITA for additional 48 hrs. The cells were then analysed for Annexin V binding by FCM. *p,0.05 versus the corresponding cells treated
with RITA in the absence of PFT-a (Student’s t test), **statistically not significant. (C) and (D) Genetic Knockdown of p53 inhibits induction of
apoptosis in MM cells. (C) MM.1S cells were exposed to 1 mM RITA for 8 hrs after transfection with scrambled or p53 siRNA for 48 hrs, cells were
harvested for analysis by Western blot, and blots were probed with specific antibodies. (D) 24 hrs after transfection of MM.1S cells with scrambled or
p53 siRNA, MM.1S cells were treated with RITA (1 mM) for additional 48 hrs, and apoptosis and cell viability was measured by FCM and MTT assay,
respectively. *p,0.05 versus the corresponding RITA treated H929 cells transfected with scrambled siRNA (Student’s t test).
doi:10.1371/journal.pone.0030215.g006
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shown). Therefore, further study will be required to understand
whether JNK can directly activate p53 in MM cells (Figure 8).
Based on our data which showed activation of JNK through
induction of phosphorylation of JNK upstream kinases, it is
unlikely that activation of JNK is mediated by direct interaction of
RITA with JNK. Nevertheless, future identification of specific
biding target(s) for RITA will improve our understanding on its
mechanisms of action and provides a rationale approach for the
development of more potent form of RITA for induction of p53-
mediated apoptosis.
Although we have provided strong evidence that activation of
JNK signaling plays a major role in activation of p53 pathway in
MM cells, we can not completely rule out the other pathways
leading to p53 activation and subsequent apoptosis of MM cells.
Therefore, we also studied the association of other possible
pathways in the apoptosis of MM cells induced by RITA as listed
in Table S2. We examined modulations of several stress response
genes such as up-regulation of ATF3, ATF4, DDIT3, and down-
regulation of XBP1 indicative of the unfolded protein response
(UPR) including the PERK-eIF2a-CHOP branch of the UPR.
Although we found the alterations of these UPR-related genes at
mRNA level by qRT-PCR, we could not confirm those changes at
the protein level by Western blot analysis (data not shown).
However, our data demonstrating a significant inhibition of p53
activation and attenuation of apoptosis upon blockage of JNK
activation suggest that JNK signaling is the major pathway in
RITA-induced apoptosis of MM cells. These results are consistent
with an earlier study in human prostate cancer cells where
inhibition of JNK activation strongly reduced p53 induction and
almost completely suppressed 2-ME-induced apoptosis [39].
Our results broaden the understanding of the novel role of c-
Jun/JNK as an apoptotic regulator in RITA-induced apoptosis of
MM cells with functional p53. To our knowledge this is the first
report describing that induction of p53-mediated apoptosis by
small molecule such as RITA is due to its ability to activate JNK.
The present findings could have implications for the design of
novel approaches to the treatment of multiple myeloma and
possibly other hematopoietic malignancies. Preclinical studies have
demonstrated the efficacy of RITA in leukemia [40] as well as in
myeloma [9]. In addition, evidence has recently been presented
indicating that RITA may potentiate the cytotoxic effects of
several novel signal transduction modulators, including MEK
Figure 7. Combination RITA and dexamethasone induces synergistic cytotoxicity in MM cell lines and primary MM samples. (A) H929
cells were treated with 1 and 2 mM RITA, in combination with 0.5 mM DXM. (B) Freshly isolated primary MM samples were for treated with 5 mM RITA
and 1 mM DXM. 48 hrs treatments of the cells, the viability were measured using MTT cell viability assays. Data are mean 6SD of triplicate samples.
*p,0.05 versus the samples treated with RITA or DXM alone (Student’s t test).
doi:10.1371/journal.pone.0030215.g007
Table 1. Affected fractions and combination indices with
RITA and DXM combination on H929 cell lines.
RITA (mM) DXM (mM)
Affected
fraction (FA)
Combination
indices (CI)
1 0.5 0.66 0.88
2 0.5 0.81 0.74
Notes; A CI of less than, equal to, and more than 1 indicates synergy, additivity,
and antagonism, respectively.
doi:10.1371/journal.pone.0030215.t001
Table 2. Combination indices and affected fractions with
RITA (5 mM) and DXM (1 mM) combination on primary MM
samples.
Sample Combination indices (CI) Affected fraction (FA)
ED50 ED75 ED90
1 0.75 0.64 0.76 0.73
2 0.73 0.66 0.75 0.67
3 0.60 0.52 0.49 0.61
Notes; A CI of less than, equal to, and more than 1 indicates synergy, additivity,
and antagonism, respectively.
doi:10.1371/journal.pone.0030215.t002
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synergistic cytotoxic response of RITA in combination with nutlin
[9]. Here, we have demonstrated that RITA potentiate the anti-
myeloma activity of DXM in both MM cell lines and patient
samples. Caspase-dependent activation of JNK and p38 MAPK by
DXM has previously been reported in eosinophil. Treatment of
eosinophil with antisense oligonucleotide of JNK1/2 resulted in
inhibition of activation of c-Jun [31]. To further examine the
significance of JNK activation in RITA-mediated apoptosis we
combined RITA with another JNK activator CDDO [32] and
examined their cytotoxic effect in MM cells. Similar to the results
obtained in combination with DXM, the combination of RITA
plus CDDO displayed a synergistic cytotoxic effect in both H929
and MM.1S cells (Figure S3). Taken together, these results suggest
that RITA potentiate the anti-myeloma activity of the drugs which
can activate JNK and the combination of RITA plus DXM may
overcome drug resistance in MM cells.
Our new observations improve understanding of the mecha-
nisms of anti-myeloma activity of RITA and thus may facilitate
translation of these findings into the clinic to improve patient
outcome in MM. These findings open an approach for the
development of anti-myeloma drug(s) with a broader spectrum.
Supporting Information
Figure S1 Networks of p53-regulated genes in MM.1S
cell lines. Ingenuity pathways analysis software (Ingenuity
Systems) was used to analyze the identified genes (n=85). The
network representing proteins involved in the biologic functions of
cancer and the cell cycle is shown. Ingenuity pathway analysis
network 1 (A) and 2 (B) depicting relationships among up- and
down-regulated genes in MM.1S cells upon RITA treatment. The
genes written in bold letters with a shaded node were identified by
microarray analysis, and the other genes were those related to the
regulated genes based on the network analysis. The intensity of a
node color indicates the degree of up-regulation (red). Nodes are
displayed using various shapes that represent the functional class of
the gene product. Edges are displayed with various labels that
describe the nature of relationship between the nodes: ___
represents direct relationship; - - - -represents indirect relationship;
Rrepresents acts on.
(TIF)
Figure S2 Synergistic activity of RITA and DXM in H929
cells (A) and primary MM samples (B). Isobologram and
FA-CI plots were produced by CalcuSyn software. The leftward
shift of the dose response curve indicates synergistic response.
Values below the threshold line represent synergistic combination.
The data shown in Figure B are representative of the 3 separate
experiments performed in different primary samples.
(TIF)
Figure S3 Combination of RITA and the known JNK
activator CDDO induces synergistic cytotoxicity in MM
cells. (A) MM.1S and H929 cells were treated with different
concentrations of CDDO (0, 0.25, 0.5, 1.0 mM). After 48 hrs, the
viability of the cells was measured by MTT assay. (B) MM.1S and
H929 cells were simultaneously treated with low doses (0.25–
1.0 mM) of RITA, and 0.5 mM CDDO for 48 hrs, followed by
assessment for cell viability using MTT assays. Data are mean
6SD of triplicate samples. *p,0.05 versus the samples treated
with RITA or CDDO alone (Student’s t test).
(TIF)
Table S1 Nucleotide sequences of the primers used for
qRT-PCR.
(DOC)
Table S2 Molecules associated with RITA-induced
signaling pathways in MM.1S cells.
(DOC)
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